Skip to main content

Table 2 Association between history of keratinocyte carcinoma and survival following diagnosis of melanoma

From: Melanoma and CLL co-occurrence and survival: role of KC history

Model factors

  

n (%)

Hazard ratio (95% confidence interval)a

Age at diagnosis (mean [SD])

62.0 (15.1)

1.04 (1.03–1.05)

Sex

 Female

2187 (39.7)

1.0 (ref.)

 Male

3324 (60.3)

1.42 (1.21–1.67)

Ethnicity

 Non-Spanish or Hispanic Origin

5402 (98.1)

1.0 (ref.)

 Spanish or Hispanic Origin

105 (1.9)

1.88 (1.21–2.93)

Year of diagnosis

 2009–2011

792 (14.4)

1.0 (ref.)

 2012–2015

2184 (39.6)

0.75 (0.63–0.89)

 2016–2020

2535 (46.0)

0.62 (0.49–0.78)

Stage at diagnosis

 Stage 1

2954 (54.6)

1.0 (ref.)

 Stage 2

1149 (21.2)

1.77 (1.38–2.28)

 Stage 3

973 (18.0)

3.13 (2.49–3.94)

 Stage 4

333 (6.2)

8.57 (6.35–11.56)

Smoking status

 Never

2686 (50.0)

1.0 (ref.)

 Former

2181 (40.6)

1.22 (1.04–1.43)

 Current

505 (9.4)

2.34 (1.85–2.97)

Drank in the last year

 No

1294 (23.7)

1.0 (ref.)

 Yes

4174 (76.3)

0.71 (0.60–0.83)

Chemotherapy as first course treatment

 No

5365 (97.4)

1.0 (ref.)

 Yes

146 (2.6)

2.93 (2.08–4.13)

History of autoimmune disease

 No

4768 (94.8)

1.0 (ref.)

 Yes

259 (5.2)

1.42 (1.06–1.91)

Breslow thickness

 Less than 1 mm

2058 (41.7)

1.0 (ref.)

 Between 1 and 2 mm

1315 (26.6)

1.38 (1.11–1.71)

 Above 2 mm

1562 (31.7)

1.60 (1.27–2.02)

Insurance status

 Private/Manage

2364 (44.6)

1.0 (ref.)

 Self Pay/Not Insured

219 (4.1)

1.06 (0.72–1.57)

 Medicaid

82 (1.5)

1.45 (0.90–2.33)

 Medicare

2478 (46.7)

1.41 (1.13–1.76)

 Tricare/VA

160 (3.0)

1.72 (1.12–2.63)

History of KC: time since melanoma diagnosisb

 History of KC: within first 4 years

1579 (28.7)2a

0.75 (0.62–0.91)

 History of KC: between 5–7 years

661 (26.7)2b

1.04 (0.73–1.47)

 History of KC: more than 7 years

211 (23.6)2c

2.79 (1.44–5.41)

  1. aThe Cox regression model was derived using a backward elimination process on a full model including the following factors: age at diagnosis, sex, race, ethnicity, year of diagnosis, stage at diagnosis, smoking status, drank in the last year, family history of melanoma, first course treatment of radiation, immunotherapy and chemotherapy, history of autoimmune disease, use of aspirin in the last year, Breslow thickness, insurance status, and history of keratinocyte carcinoma (bolded variables were retained in the final model)
  2. bThe frequency and percentage of patients who self-reported history of keratinocyte carcinoma among the 2afull cohort, among 2bpatients who had at least 4 years of follow-up, and among 2cpatients who had at least 7 years of follow-up
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us